Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.

导出 OA

翻译打印收藏纠错

第一作者： Nicholas A,Marston

第一单位： TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., F.K.K., F.N., Y.G., R.P.G., M.S.S., C.T.R.).

作者： Nicholas A,Marston ^[1] ; Frederick K,Kamanu ^[1] ; Francesco,Nordio ^[1] ; Yared,Gurmu ^[1] ; Carolina,Roselli ^[2] ; Peter S,Sever ^[3] ; Terje R,Pedersen ^[4] ; Anthony C,Keech ^[5] ; Huei,Wang ^[6] ; Armando,Lira Pineda ^[7] ; Robert P,Giugliano ^[7] ; Steven A,Lubitz ^[1] ; Patrick T,Ellinor ^[2] ; Marc S,Sabatine ^[8] ; Christian T,Ruff ^[2]

作者单位： TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., F.K.K., F.N., Y.G., R.P.G., M.S.S., C.T.R.). ^[1] Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard Cambridge, MA (C.R., S.A.L., P.T.E.). ^[2] University Medical Center Groningen, University of Groningen, the Netherlands (C.R.). ^[3] National Heart and Lung Institute, Imperial College London, United Kingdom (P.S.S.). ^[4] Oslo University Hospital, Ulleval and Medical Faculty, University of Oslo, Norway (T.R.P.). ^[5] Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia (A.C.K.). ^[6] Amgen, Thousand Oaks, CA (H.W., A.L.P.). ^[7] Cardiovascular Research Center, Massachusetts General Hospital, Boston (S.A.L., P.T.E.). ^[8]

关键词 PCSK9 protein, human cardiovascular disease evolocumab genetics risk factors